adMare Industry Builder Series Featuring Roberto Bellini

Building a Biotech Success from Failure

Recently, we witnessed a major success for the Canadian life science industry with Bellus Health’s acquisition by GSK for US$2B to continue the development of camlipixant, a potential best-in-class P2X3 antagonist for the treatment of refractory chronic cough. Bellus acquired camlipixant from NEOMED Institute/adMare BioInnovations in 2017 and proceeded to advance its development from preclinical to Phase III while generating a 20-fold return for investors. 

adMare is pleased to welcome Roberto Bellini, former President and CEO of BELLUS Health to our next adMare Industry Builder series, where he will discuss how setbacks along the Bellus journey shaped the Company’s strategy and eventual success. His presentation will be followed by a Q&A period, where you will have the opportunity to ask your questions and discuss with Mr. Bellini.

Join us on September 19th at 12 PM ET to discover this success story!
 

Click here to register

About Roberto Bellini

Roberto Bellini served as President and CEO of BELLUS Health between January 2010 and July 2023. Under his leadership, BELLUS Health developed a P2X3 antagonist, camlipixant, for chronic cough from preclinical to Phase 3 and was acquired by GSK plc for US$2B in 2023. Mr. Bellini previously oversaw the licensing and partnering activities of BELLUS Health.

His experience includes several roles and responsibilities at Picchio Pharma Inc., a joint venture healthcare investment firm owned by the Bellini Family Trust and Power Corporation of Canada, and its investee companies.

Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.